Diphtheria Market Size Forecast: Revenue and CAGR by 2029

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Expected Total Market Size Of The Diphtheria Industry By The Forecast Year 2029?

The diphtheria market has seen substantial growth in recent years. It is anticipated to expand from $8.91 billion in 2024 to $9.39 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 5.4%. The historical expansion can be attributed to advancements in vaccine development, widespread immunization campaigns, enhanced awareness, and improvements in healthcare infrastructure.

The diphtheria market size is projected to experience substantial growth over the coming years. It is forecast to reach $12.1 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 6.5%. This expansion during the forecast period is propelled by factors such as emerging outbreaks, ongoing booster vaccination programs, increased global travel and migration, and enhanced public health preparedness. Prominent trends within this period are expected to encompass combination vaccines, the application of telemedicine for vaccination, various vaccine equity initiatives, and the formation of public-private partnerships.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13016&type=smp

What Are The Emerging Market Drivers Creating New Opportunities In The Diphtheria Industry?

The increasing incidence of bacterial infections is projected to fuel the expansion of the diphtheria market moving forward. A bacterial infection signifies an illness or condition resulting from the presence and growth of bacteria or the toxins they produce when invading the body. Diphtheria is a grave infection caused by bacterial strains that compromise the immune system and facilitate the multiplication of Corynebacterium diphtheria. For instance, in September 2024, GOV.UK, a UK-based government website, stated that during the fiscal year 2022 to 2023, NHS acute trusts in England recorded a total of 38,757 E. coli bacteremia cases, with 7,881 cases (20.3%) identified as infections acquired in a hospital setting. Thus, the rising prevalence of bacterial infections will be a driving force for the diphtheria market.

What Are The Emerging Segments Gaining Attention In The Diphtheria Market?

The diphtheriamarket covered in this report is segmented –

1) By Type: Diphtheria; Skin Diphtheria; Other Types

2) By Diagnosis: Physical Examination; Throat Culture; Other Diagnosis

3) By Treatment: Antibiotics; Antitoxin; Other Treatments

4) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy

5) By End-Users: Hospitals; Homecare; Specialty Clinics; Other End-Users

Subsegments:

1) By Diphtheria: Respiratory Diphtheria; Non-respiratory Diphtheria

2) By Skin Diphtheria: Cutaneous Diphtheria

3) By Other Types: Diphtheritic Myocarditis; Diphtheritic Neuritis

Which Market Trends Are Creating New Opportunities In The Diphtheria Industry?

Leading companies active in the diphtheria market are engaged in developing innovative medications and securing regulatory approvals to maintain their position. For example, in October 2022, GlaxoSmithKline PLC, a pharmaceutical and biotechnology company based in the UK, announced that the US Food and Drug Administration (FDA) approved BOOSTRIX (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, adsorbed; Tdap) for immunization during the third month of pregnancy. This aims to help prevent pertussis (whooping cough) in infants younger than two months of age. The Tdap immunization given during pregnancy provides the highest level of protection against whooping cough for newborns in their early months of life. When pregnant women are immunized, protective antibodies are transferred from the mother to her child.

Who Are The Primary Competitors In The Global Diphtheria Market?

Major companies operating in the diphtheria market are Pfizer Inc., Johnson & Johnson Co, Roche Holding AG, Merck & Co Inc., AbbVie Inc., Novartis AG, Sanofi SA, Bristol-Myers Squibb Co., AstraZeneca PLC, GlaxoSmithKline PLC, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Moderna Inc., BioNTech SE, Regeneron Pharmaceuticals Inc., Biogen Inc., Vertex Pharmaceuticals Inc., Serum Institute of India, Novavax Inc., Sinovac Biotech Ltd., Emergent BioSolutions Inc., Dynavax Technologies Corporation, Bharat Biotech International Limited, CureVac AG, Inovio Pharmaceuticals Inc., The Native Antigen Company.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/diphtheria-global-market-report

How Is Diphtheria Market Demand Varying Across Different Regions?

Asia-Pacific was the largest region in the diphtheria market in 2024. The regions covered in diphtheria market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Request A Customized Version Of The Diphtheria Market Report:

https://www.thebusinessresearchcompany.com/customise?id=13016&type=smp

Browse Through More Reports Similar to the Global Diphtheria Market 2025, By The Business Research Company

Generic Pharmaceuticals Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/generic-pharmaceuticals-global-market-report

Pharmacies And Drug Stores Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/pharmacies-and-drug-stores-global-market-report

Pharmaceutical Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/pharmaceutical-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795